Oncolytic Tanapoxvirus for the Treatment of Human Colorectal Cancer
- 詳細技術說明
- Cancer Therapy using Engineered Tanapox Virus: Wild-type tanapox virus (TPV) causes very mild illness and is not transmitted from person to person making it desirable for cancer therapy.
- *Abstract
-
Globally, colorectal cancer in humans (hCRC) is the second-most common cancer in women and the third-most common in men. In the United States, the five-year survival rate for patients with all stages of hCRC improved by 14% between 1977 and 2006, from 51% to 65%. However, established therapies are often inadequate for patients with advanced disease. For patients with advanced stage hCRC (stage III or IV), the five-year survival rate is less than 20%. New treatments and treatment modalities are desperately needed.
Recognition that the body’s immune system can be mobilized to help fight cancer has recently led to multiple therapeutic modalities that activate the body’s innate and/or adaptive immune system. One new modality is oncolytic viruses that are engineered to assist the host immune system to recognize and attack cancer cells.
Specifically, tanapox virus (TPV) is an attractive candidate for oncolytic virotherapy. TPV infected humans experience only a mild and self-limiting febrile illness, in part because TPV infection is normally confined to peripheral areas of the body. Additionally, TPV has never been observed to transmit from person to person, a highly desirable safety feature in an oncolytic virus.
- 國家/地區
- 美國
